Development and innovation

Adamed’s strategic partnership on the Italian Market

17 June 2019

The strategic partnership with Ecupharma will help Adamed grow on the Italian market in scope of cardiology as well as other therapy areas in the future. The Italian medicinal product market – valued at almost EUR 20 billion – is the third-biggest one in the European Union, after Germany and France. It continues to grow at a stable pace and is dominated by generic and off-patent products (which compose approx. 90% of the market).

Ecupharma’s portfolio focuses on chronic diseases. The company is building a stable market position on patient loyalty. It also responds to contemporary demographic challenges by focusing on ailments among the elderly, which Adamed does as well.

Ecupharma competes with the leading players in Italy and is the market leader in certain molecules used in treatment of central nervous system disorders. The company, which was founded in 1993 by Luciano Grottola, is still administrated by the family and supported by the Serpero Foundation.

Along with the investment in Ecupharma, Adamed also opened another international branch in Italy. In the past, the company’s presence on this market was limited to the business-to-business segment, but the high potential and growth perspectives encouraged the management board of Adamed Pharma to establish commercial structures in Italy.

Adamed’s international expansion

The company’s consistent development strategy based on two foundations – innovation and international expansion – has turned Adamed into a well-known international brand. The company’s products, which are available in dozens of countries on six continents, are associated with top quality and innovation. The company holds over 190 patents. Adamed currently has nine branches abroad – in Spain, Russia, Vietnam, Kazakhstan, Uzbekistan, Ukraine, the Czech Republic, Slovakia, and the newest one in Italy.

Adamed’s investments are not limited to Europe. In 2017, the company acquired a package of controlling shares in Dat Vi Phu Pharmaceutical, one of the fastest-growing pharmaceutical companies in Vietnam. Adamed is currently modernising the production process and machine parks at the factories of Dat Vi Phu in order to implement European drug production standards – EU GMP – in early 2021.

Adamed is a net exporter – an enterprise adding value in Polish trade. The company almost doubled the value of its exported products over the past four years with a compound annual growth rate (CAGR) of 21.6% in the years 2012-2017.